Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 >= 50%: Results from EMPOWER-Lung 1 study.
Tarih
2021Yazar
Ozguroglu, Mustafa
Gogishvili, Miranda
Turk, Haci M.
Gumus, Mahmut
Chen, Chieh-I
Ivanescu, Cristina
Kilickap, Saadettin
Bondarenko, Igor
Cicin, Irfan
Harnett, James
Mastey, Vera
Naumann, Ulrike
Reaney, Matthew
Konidaris, Gerasimos
Sasane, Medha
Brady, Keri
Li, Siyu
Gullo, Giuseppe
Rietschel, Petra
Sezer, Ahmet
Üst veri
Tüm öğe kaydını gösterBağlantı
http://hdl.handle.net/20.500.12627/172416https://doi.org/10.1200/jco.2021.39.15_suppl.9078
Koleksiyonlar
- Makale [92796]